JP4704712B2 - 心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動を誘発させた動物を用いた心房細動抑制剤の評価方法 - Google Patents
心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動を誘発させた動物を用いた心房細動抑制剤の評価方法 Download PDFInfo
- Publication number
- JP4704712B2 JP4704712B2 JP2004257448A JP2004257448A JP4704712B2 JP 4704712 B2 JP4704712 B2 JP 4704712B2 JP 2004257448 A JP2004257448 A JP 2004257448A JP 2004257448 A JP2004257448 A JP 2004257448A JP 4704712 B2 JP4704712 B2 JP 4704712B2
- Authority
- JP
- Japan
- Prior art keywords
- atrial fibrillation
- atrial
- inducing
- induced
- atrium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010003658 Atrial Fibrillation Diseases 0.000 title claims description 151
- 241001465754 Metazoa Species 0.000 title claims description 28
- 238000000034 method Methods 0.000 title claims description 20
- 230000001939 inductive effect Effects 0.000 title claims description 15
- 239000003112 inhibitor Substances 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title description 6
- 201000002931 third-degree atrioventricular block Diseases 0.000 claims description 29
- 230000000638 stimulation Effects 0.000 claims description 27
- 210000002837 heart atrium Anatomy 0.000 claims description 19
- 210000001013 sinoatrial node Anatomy 0.000 claims description 14
- 210000003157 atrial septum Anatomy 0.000 claims description 10
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 230000001746 atrial effect Effects 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 238000001467 acupuncture Methods 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 description 40
- 239000003814 drug Substances 0.000 description 35
- 229940079593 drug Drugs 0.000 description 34
- 238000012360 testing method Methods 0.000 description 31
- 241000700159 Rattus Species 0.000 description 29
- 238000011156 evaluation Methods 0.000 description 25
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 14
- 239000002504 physiological saline solution Substances 0.000 description 10
- 210000003191 femoral vein Anatomy 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 8
- 210000003238 esophagus Anatomy 0.000 description 7
- 229960001412 pentobarbital Drugs 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 210000001992 atrioventricular node Anatomy 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 210000005245 right atrium Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BCQTVJKBTWGHCX-UHFFFAOYSA-N pilsicainide Chemical compound CC1=CC=CC(C)=C1NC(=O)CC1(CCC2)N2CCC1 BCQTVJKBTWGHCX-UHFFFAOYSA-N 0.000 description 4
- 229950010769 pilsicainide Drugs 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000005246 left atrium Anatomy 0.000 description 3
- 208000008494 pericarditis Diseases 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000004375 bundle of his Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 2
- 229960001066 disopyramide Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000010349 pulsation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 206010048623 Atrial hypertrophy Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013210 evaluation model Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011867 re-evaluation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/361—Detecting fibrillation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
完全房室ブロック犬の作製
生後約1年の雌のビーグル犬(約10kg)にペントバルビタールをゆっくり静注し(30mg/kg)し、同時に気管に人工呼吸器を挿管して一定量(20ml/kg)の酸素又は大気を供給して人工呼吸させる。大腿部を剃毛し、アルコール綿で消毒してから、大腿静脈にガイドワイヤを挿入し、さらにペーシング電極が先端部に取り付けられた電極カテーテルを大腿静脈から右心室まで挿入する。そして、ヒス束心電図が最大に記録できる部位を探して先端の電極を固定する。次に、電極カテーテルの先端電極から房室結節領域に高周波(500kHz 20W)を10秒間通電して房室結節を破壊し、房室伝導をブロックすることで完全房室ブロック犬を作製した。
心房細動持続時間による薬物評価試験1
この薬物評価試験1には、前記実施例1で作製された完全房室ブロック犬を使用し、術後約4〜6ヶ月を経過したモデルである。心房細動を人工的に誘発させる方法は、前記完全房室ブロック犬を作製する場合と同様、完全房室ブロック犬にペントバルビタールをゆっくり静注し(30mg/kg)し、同時に気管に挿管して人工呼吸器から一定量(20ml/kg)の酸素又は大気を供給して人工呼吸させる。その状態で大腿静脈から電極カテーテルを右心房内に挿入し、洞結節を電気刺激する。この時の電気刺激は、60Vの電圧を、60ms間隔で約10秒間加える。
心房細動持続時間による薬物評価試験2
この薬物評価試験2にはラットを使用した。ラットに心房細動を人工的に誘発させる方法は、上述した完全房室ブロック犬の場合と同様である、先ず、ラットにペントバルビタールをゆっくり腹腔内投与し(50mg/kg)し、同時に気管に挿管した人工呼吸器から一定量(10ml/kg)の酸素又は大気を供給して呼吸を安定させる。この状態で、電極カテーテルを食道に挿入し、食道から心房を電気刺激することで心房細動を誘発させた。この時の電気刺激は、閾値の約1.5倍の電圧を12ms間隔で約30秒間加える。
心房細動誘発率による薬物評価試験
この薬物評価試験には、前記実施例1で作製された完全房室ブロック犬を使用した。また、電気刺激を与えて心房細動を人工的に誘発させる方法も実施例1と同様である。この実施例4では時間的間隔を置きながら電気刺激を10回行い、その内で何回心房細動を誘発したかを記録する。そして、心房細動が収まった直後にピルジカイニド(1mg/kg)を大腿静脈内にゆっくり時間を掛けて投与し、投与後15分、30分、45分、60分後に再び電気刺激を10回与えて、その時に発生した心房細動を記録する。これとは別に、前記ピルジカイニドの代わりにコントロールとして生理食塩水(1ml/kg)を投与して同様の試験を行なった。
前記実施例3において、ラットに電気刺激を与えた時の心拍数、血圧及び心電図の各指標であるQT間隔「電気的心室脱再分極時間」、PR間隔「房室伝導時間」、QRS幅「心室興奮時間」についての評価を行なった。電気刺激の条件、ピルジカイニド投与量、投与後の計測経過時間は前記実施例3と同様である。その結果を図6、図7及び図8にそれぞれ示す。図6〜図8において、縦軸はそれぞれ心拍数、血圧、QT間隔・PR間隔・QRS幅を示し、横軸はいずれもピルジカイニド投与後の経過時間を示す。なお、この評価試験でにおいても、ピルジカイニドの代わりに生理食塩水を投与して同様の評価を行なった。
Claims (6)
- イヌの房室結節領域に電極カテーテルを挿入し、前記電極カテーテルから前記房室結節領域に高周波を通電して前記房室結節を破壊し、房室伝導をブロックすることによって、心房が肥大化されたこと特徴とする心房細動モデル動物。
- 請求項1に記載の心房細動モデル動物の心房内に電極カテーテルを挿入し、洞結節又は心房中隔を電気刺激することによって心房細動を再現性をもって誘発させる方法。
- 前記洞結節又は心房中隔への電気刺激が10秒以上行なわれる請求項2に記載の心房細動を誘発させる方法。
- 前記心房細動モデル動物が完全房室ブロック犬である請求項2から3のいずれかに記載の心房細動を誘発させる方法。
- 請求項1に記載の心房細動モデル動物の心房を電気刺激して心房細動を誘発させた時の心房細動持続時間を計測し、その心房細動が収まった直後に心房細動抑制剤を投与し、投与後所定時間毎に再び同様の方法で心房細動を誘発させ、その時の心房細動継続時間を計測して、心房細動抑制剤の投与前の心房細動持続時間と比較することを特徴とする心房細動抑制剤の評価方法。
- 請求項1に記載の心房細動モデル動物の心房を電気刺激した時に心房細動が誘発される頻度と、心房細動抑制剤を投与した後、所定時間毎に再び同様の方法で心房細動が誘発される頻度とを比較することを特徴とする心房細動抑制剤の評価方法。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004257448A JP4704712B2 (ja) | 2004-09-03 | 2004-09-03 | 心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動を誘発させた動物を用いた心房細動抑制剤の評価方法 |
PCT/JP2005/015914 WO2006025450A1 (ja) | 2004-09-03 | 2005-08-31 | 心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動抑制剤の評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004257448A JP4704712B2 (ja) | 2004-09-03 | 2004-09-03 | 心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動を誘発させた動物を用いた心房細動抑制剤の評価方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011015743A Division JP5358592B2 (ja) | 2011-01-27 | 2011-01-27 | 心房細動を誘発させる方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006067950A JP2006067950A (ja) | 2006-03-16 |
JP4704712B2 true JP4704712B2 (ja) | 2011-06-22 |
Family
ID=36000100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004257448A Active JP4704712B2 (ja) | 2004-09-03 | 2004-09-03 | 心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動を誘発させた動物を用いた心房細動抑制剤の評価方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4704712B2 (ja) |
WO (1) | WO2006025450A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5039236B1 (ja) | 2011-04-27 | 2012-10-03 | 学校法人東邦大学 | 抗不整脈剤及び心房細動抑制剤 |
JP5615868B2 (ja) * | 2011-04-27 | 2014-10-29 | 学校法人東邦大学 | 持続性心房細動モデル及びその製造方法、並びに、心房細動抑制剤のスクリーニング方法 |
JP5918038B2 (ja) * | 2011-06-29 | 2016-05-18 | 学校法人東邦大学 | 持続型心房細動モデル、その持続型心房細動誘発方法及び製造方法 |
CN103519786B (zh) * | 2013-10-11 | 2015-04-22 | 上海交通大学 | 用于自由运动动物的微型脑卒中病理诱导系统 |
CN111657927B (zh) * | 2020-07-20 | 2023-12-08 | 杭州市第一人民医院 | 电诱颤装置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870974A (en) * | 1987-09-30 | 1989-10-03 | Chinese Pla General Hospital | Apparatus and method for detecting heart characteristics by way of electrical stimulation |
-
2004
- 2004-09-03 JP JP2004257448A patent/JP4704712B2/ja active Active
-
2005
- 2005-08-31 WO PCT/JP2005/015914 patent/WO2006025450A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006025450A1 (ja) | 2006-03-09 |
JP2006067950A (ja) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kadowitz et al. | Effect of sympathetic nerve stimulation on pulmonary vascular resistance in the dog | |
US9295846B2 (en) | Muscle and nerve stimulation | |
US7195013B2 (en) | Systems and methods for modulating autonomic function | |
DE60121458T2 (de) | Medizinische vorrichtung zur blutstromsteuerung | |
AU2005249498B2 (en) | Methods for treating a mammal before, during and after cardiac arrest | |
Hilton et al. | The pattern of cardiovascular response to carotid chemoreceptor stimulation in the cat. | |
JP2004500906A (ja) | 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド | |
Eldridge | Expiratory effects of brief carotid sinus nerve and carotid body stimulations | |
WO2023065684A1 (zh) | 辛酸钠在制备改善心肺复苏效果以及心肺复苏后多器官功能障碍的药物中的应用 | |
Pickar et al. | Stimulation of vagal afferents inhibits locomotion in mesencephalic cats | |
WO2006025450A1 (ja) | 心房細動モデル動物の作製方法、心房細動を誘発させる方法及び心房細動抑制剤の評価方法 | |
Kimberly et al. | Transvenous Electrical Cardioversion of Equine Atrial Fibrillation Technical Considerations | |
JP5358592B2 (ja) | 心房細動を誘発させる方法 | |
McBean et al. | Neuroprotective efficacy of lifarizine (RS‐87476) in a simplified rat survival model of 2 vessel occlusion | |
Pagani et al. | Respiratory and cardiovascular effects of intraventricular cholecystokinin | |
JP5918038B2 (ja) | 持続型心房細動モデル、その持続型心房細動誘発方法及び製造方法 | |
Walker et al. | Pacing failure due to flecainide acetate | |
Kushiku et al. | Cardiovascular effects of brovincamine and possible mechanisms involved | |
Pye et al. | Early recognition with capnography, and successful resuscitation, of severe cardiac dysfunction in a horse receiving amiodarone during transvenous electric cardioversion (TVEC) | |
Monti et al. | Treatment with lipid therapy to resuscitate a patient suffering from toxicity due to local anesthetics | |
KR20070035517A (ko) | 심장 정지 전, 중 및 후의 포유동물 치료방법 | |
US8841292B2 (en) | Induced hypothermia | |
Rosenheck et al. | The effect of overdrive pacing rate and duration on ventricular escape rhythms in patients with chronic complete atrioventricular block | |
Willems et al. | Effect of different pacing protocols on the induction of atrial fibrillation in a transvenously paced sheep model | |
Kopczyñska et al. | Response of respiratory muscles to intravenous nicotine challenge in anaesthetized cats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070822 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100810 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20101007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20101115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110308 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110310 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4704712 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |